Published by Global Banking & Finance Review®
Posted on February 25, 2026
2 min readLast updated: April 2, 2026
Add as preferred source on Google
Novonesis missed Q4 sales forecasts as Agriculture, Energy & Tech stalled, leaving EBITDA just under consensus. The company guided 2026 organic growth of 5–7% and a 37–38% margin amid currency headwinds.
Feb 25 (Reuters) - Danish biosolutions company Novonesis reported weaker-than-expected organic sales growth for the fourth quarter on Wednesday, held back by flat revenue in the Agriculture, Energy & Tech business.
While the unit's euro sales were positively impacted by the 2025 acquisition of the remaining stake in Feed Enzyme Alliance, this boost was offset by currency headwinds elsewhere, Novonesis said in a statement, another European chemicals group grappling with strong home currencies eroding reported numbers.
KEY DETAILS
* Novonesis delivered quarterly organic growth of 4%,against 5.2% seen in a company-provided consensus. * The biggest miss to analysts' expectations came within thePlanetary Health segment, where Agriculture, Energy & Tech sawno growth in euros versus 7% expected by analysts. * Negative timing in the agriculture segment and a toughcomparison period in tech hindered growth, despite positivedevelopment in the energy business area, the company said in apresentation. * "We delivered double digit growth in bioenergy in Q4, andwe're already seeing a strong start to 2026," CEO Ester Baigettold Reuters. * Quarterly adjusted earnings before interest, taxes,depreciation and amortization (EBITDA) were 364.6 million euros($429.9 million), 10 million euros below consensus. * For 2026, Novonesis guides for organic sales growthbetween 5-7% and a higher adjusted EBITDA margin of 37-38%,including currency headwinds of about 50 bps year-on-year. * Jyske Bank analysts said that late‑year signs of consumersoftness were hardly encouraging after a strong year. * Novonesis' shares have lost around 20% of their valuesince peaking in June 2025. They were down less than 2% at 1135GMT.($1 = 0.8480 euros)
(Reporting by Izabela Niemiec in Gdansk, editing by Milla Nissi-Prussak)
Novonesis’ fourth‑quarter results missed sales expectations as growth stalled in its Agriculture, Energy & Tech unit, prompting a cautious 2026 outlook for growth and margins.
The unit saw flat growth versus expectations. While euro‑reported sales were helped by the 2025 Feed Enzyme Alliance acquisition, currency headwinds and softness elsewhere offset the boost.
Management targets 5–7% organic sales growth and a 37–38% adjusted EBITDA margin, factoring in continued currency headwinds and execution on pricing and synergy initiatives.
Explore more articles in the Finance category
